Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5250_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Contents
- •1.1.2.5 Priming (Guiding) Transcranial Magnetic Stimulation (pTMS)
- •1.1.2.6 Synchronized Transcranial Magnetic Stimulation (sTMS)
- •1.1.2.8 Magnetic Seizure Therapy (MST)
- •1.2.1 Treatment Procedures
- •1.2.2 TMS Treatment Precautions
- •1.2.2.1 Seizure Risk
- •1.2.2.3 Other Precautions
- •1.3.1.1 Membrane Potential Alterations
- •1.4 Effect Factors
- •1.4.1 Stimulation Frequency
- •About the Editors
- •1: Transcranial Magnetic Stimulation
- •1.1 Introduction
- •1.1.2.1 Repetitive Transcranial Magnetic Stimulation (rTMS)
- •1.1.2.2 Prolonged Intermittent Theta Burst Stimulation (piTBS)
- •1.1.2.4 Deep Transcranial Magnetic Stimulation (dTMS)
- •1.4.2 Stimulation Intensity
- •1.4.3 Pulse Duration
- •1.4.5 Interstimulus Interval
- •1.5 Conclusion
- •References
- •2: Transcranial Direct Current Stimulation
- •2.1 Introduction
- •2.3.3 Nonneuronal Mechanisms
- •2.3.4 Others
- •2.4 Effect Factors
- •2.4.1 Stimulus Polarity
- •2.4.2 Duration
- •2.4.3 Current Intensity
- •2.4.4 Others
- •2.5 Summary and Outlook
- •References
- •3: Major Depressive Disorder
- •3.1 Introduction
- •3.2 TMS
- •3.2.1 rTMS
- •3.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.2 Deep TMS
- •3.2.2.1 Efficacy
- •3.2.2.2 Safety
- •3.2.2.3 Treatment Regimen
- •3.2.2.4 Clinical Recommendations
- •3.2.3 Priming rTMS
- •3.2.3.1 Efficacy
- •3.2.3.2 Safety
- •3.2.3.3 Treatment Regimen
- •3.2.3.4 Clinical Recommendations
- •3.2.4 Synchronized rTMS
- •3.2.4.1 Efficacy
- •3.2.4.2 Safety
- •3.2.4.3 Treatment Regimen
- •3.2.4.4 Clinical Recommendations
- •3.2.5 TBS
- •3.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.5.3 Continuous TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.6 Magnetic Seizure Therapy (MST)
- •3.2.6.1 Efficacy
- •3.2.6.2 Safety
- •3.2.6.3 Treatment Regimen
- •3.2.6.4 Clinical Recommendations
- •3.3 tDCS
- •3.3.1 Conventional tDCS
- •3.3.1.1 Efficacy
- •3.3.1.3 Treatment Regimen
- •3.3.1.4 Clinical Recommendations
- •3.3.2 HD-tDCS
- •3.3.2.1 Efficacy
- •3.3.2.2 Safety
- •3.3.2.3 Treatment Regimen
- •3.3.2.4 Clinical Recommendations
- •3.4 TMS Vs. tDCS
- •3.4.1 Efficacy
- •3.4.2 Safety
- •3.5 Conclusion
- •References
- •3.3.1.2 Safety
- •4: Bipolar Disorder
- •4.1 Introduction
- •4.2 TMS
- •4.2.1 rTMS
- •4.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.2 Deep TMS
- •4.2.2.1 Efficacy
- •4.2.2.2 Safety
- •4.2.2.3 Treatment Regimen
- •4.2.2.4 Clinical Recommendations
- •4.2.3 Priming TMS
- •4.2.3.1 Efficacy
- •4.2.3.2 Safety
- •4.2.3.3 Treatment Regimen
- •4.2.3.4 Clinical Recommendations
- •4.2.4 Synchronized TMS
- •4.2.4.1 Efficacy
- •4.2.4.2 Safety
- •4.2.4.3 Treatment Regimen
- •4.2.4.4 Clinical Recommendations
- •4.2.5 TBS
- •4.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.5.3 Continuous TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.6 MST
- •4.2.6.1 Efficacy
- •4.2.6.2 Safety
- •4.2.6.3 Treatment Regimen
- •4.2.6.4 Clinical Recommendations
- •4.3 tDCS
- •4.3.1 Conventional tDCS
- •4.3.1.1 Efficacy
- •4.3.1.2 Safety
- •4.3.1.3 Treatment Regimen
- •4.3.1.4 Clinical Recommendations
- •4.3.2 HD-tDCS
- •4.3.2.1 Efficacy
- •4.3.2.2 Safety
- •4.3.2.3 Treatment Regimen
- •4.3.2.4 Clinical Recommendations
- •4.4 TMS vs. tDCS
- •4.4.1 Efficacy
- •4.4.2 Safety
- •4.5 Conclusion
- •References
- •5: Schizophrenia
- •5.1 Schizophrenia
- •5.2 TMS
- •5.2.1 rTMS
- •5.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.2 Deep TMS
- •5.2.2.1 Efficacy
- •5.2.2.2 Safety
- •5.2.2.3 Treatment Regimen
- •5.2.2.4 Clinical Recommendations
- •5.2.3 Priming TMS
- •5.2.3.1 Efficacy
- •5.2.3.2 Safety
- •5.2.3.3 Treatment Regimen
- •5.2.3.4 Clinical Recommendations
- •5.2.4 Synchronized TMS
- •5.2.4.1 Efficacy
- •5.2.4.2 Safety
- •5.2.4.3 Treatment Regimen
- •5.2.4.4 Clinical Recommendations
- •5.2.5 TBS
- •5.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.6 MST
- •5.2.6.1 Efficacy
- •5.2.6.2 Safety
- •5.2.6.3 Treatment Regimen
- •5.2.6.4 Clinical Recommendations
- •5.3 tDCS
- •5.3.1 Conventional tDCS
- •5.3.1.1 Efficacy
- •5.3.1.2 Safety
- •5.3.1.3 Treatment Regimen
- •5.3.1.4 Clinical Recommendations
- •5.3.2 HD-tDCS
- •5.3.2.1 Efficacy
- •5.3.2.2 Safety
- •5.3.2.3 Treatment Regimen
- •5.3.2.4 Clinical Recommendations
- •5.4 TMS vs. tDCS
- •5.4.1 Efficacy
- •5.4.2 Safety
- •5.5 Conclusion
- •References
- •6: Addictive Disorders
- •6.1 Addictive Disorders
- •6.2 TMS
- •6.2.1 rTMS
- •6.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •6.2.1.2 Bilateral rTMS
- •6.2.1.3 Accelerated rTMS
- •6.2.2 Deep TMS
- •6.2.3 Priming TMS
- •6.2.4 Synchronized TMS
- •6.2.5 TBS
- •6.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •6.2.5.2 Accelerated iTBS
- •6.2.5.3 Continuous TBS
- •6.2.5.4 Bilateral TBS
- •6.2.6 MST
- •6.3 tDCS
- •6.3.1 Conventional tDCS
- •6.3.1.1 Efficacy
- •6.3.1.2 Safety
- •6.3.1.3 Treatment Regimen
- •6.3.1.4 Clinical Recommendations
- •6.3.2 HD-tDCS
- •6.4 TMS vs. tDCS
- •6.4.1 Efficacy
- •6.4.2 Safety
- •6.5 Conclusion
- •References
- •7: Obsessive-Compulsive Disorder
- •7.1 Introduction
- •7.2 TMS
- •7.2.1 rTMS
- •7.2.1.1 Unilateral rTMS
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.2 Deep TMS
- •7.2.2.1 Efficacy
- •7.2.2.2 Safety
- •7.2.2.3 Treatment Regimen
- •7.2.2.4 Clinical Recommendations
- •7.2.3 Priming TMS
- •7.2.3.1 Efficacy
- •7.2.3.2 Safety
- •7.2.3.3 Treatment Regimen
- •7.2.3.4 Clinical Recommendations
- •7.2.4 Synchronized TMS
- •7.2.4.1 Efficacy
- •7.2.4.2 Safety
- •7.2.4.3 Treatment Regimen
- •7.2.4.4 Clinical Recommendations
- •7.2.5 TBS
- •7.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.6 MST
- •7.2.6.1 Safety
- •7.2.6.2 Treatment Regimen
- •7.2.6.3 Clinical Recommendations
- •7.3 tDCS
- •7.3.1 Conventional tDCS
- •7.3.1.1 Efficacy
- •7.3.1.2 Safety
- •7.3.1.3 Treatment Regimen
- •7.3.1.4 Clinical Recommendations
- •7.3.2 HD-tDCS
- •7.3.2.1 Efficacy
- •7.3.2.2 Safety
- •7.3.2.3 Treatment Regimen
- •7.3.2.4 Clinical Recommendations
- •7.4 TMS vs. tDCS
- •7.4.1 Efficacy
- •7.4.2 Safety
- •7.5 Conclusion
- •References
- •8: Attention Deficit Hyperactivity Disorder
- •8.1 ADHD
- •8.1.2 Therapeutic Method
- •8.2 TMS
- •8.2.1 Single-Pulse TMS (spTMS)
- •8.2.1.1 Efficacy
- •8.2.1.2 Safety
- •8.2.1.3 Treatment Regimen
- •8.2.1.4 Clinical Recommendations
- •8.2.2 Paired-Pulse TMS (ppTMS)
- •8.2.2.1 Efficacy
- •8.2.2.2 Safety
- •8.2.2.3 Treatment Regimen
- •8.2.2.4 Clinical Recommendations
- •8.2.3 rTMS
- •8.2.3.1 Low-Frequency rTMS (LF-rTMS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.2.3.2 High-Frequency rTMS (HF-rTMS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.2.4 TBS
- •8.2.4.1 Intermittent TBS (iTBS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.2.4.2 Continuous iTBS (cTBS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.3 tDCS
- •8.3.1 Conventional tDCS
- •8.3.1.1 Efficacy
- •8.3.1.2 Safety
- •8.3.1.3 Treatment Regimen
- •8.3.1.4 Clinical Recommendations
- •8.3.2.1 Efficacy
- •8.3.2.2 Safety
- •8.3.2.3 Treatment Regimen
- •8.3.2.4 Clinical Recommendations
- •8.4 TMS vs. tDCS
- •8.4.1 Efficacy
- •8.4.2 Safety
- •8.5 Conclusion
- •References
- •9: Autism Spectrum Disorder
- •9.1 Introduction
- •9.2 rTMS
- •9.2.1 Unilateral rTMS
- •9.2.1.1 Efficacy
- •9.2.1.2 Safety
- •9.2.1.3 Treatment Regimen
- •9.2.1.4 Clinical Recommendations
- •9.2.1.5 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.1.6 Accelerated rTMS
- •9.2.2 Deep TMS
- •9.2.2.1 Efficacy
- •9.2.2.2 Safety
- •9.2.2.3 Treatment Regimen
- •9.2.2.4 Clinical Recommendations
- •9.2.3 Priming TMS
- •9.2.4 Synchronized TMS
- •9.2.5 TBS
- •9.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.5.2 Accelerated iTBS
- •9.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.6 MST
- •9.3 tDCS
- •9.3.1 Conventional tDCS
- •9.3.1.1 Efficacy
- •9.3.1.2 Safety
- •9.3.1.3 Treatment Regimen
- •9.3.1.4 Clinical Recommendations
- •9.3.2 HD-tDCS
- •9.3.2.1 Efficacy
- •9.3.2.2 Safety
- •9.3.2.3 Treatment Regimen
- •9.3.2.4 Clinical Recommendations
- •9.4 TMS Vs. tDCS
- •9.4.1 Efficacy
- •9.4.1.1 Cognitive Effects
- •9.4.1.3 Biological Effects
- •9.4.2 Safety
- •9.5 Conclusion
- •References
- •10: Anxiety Disorder
- •10.1 Introduction
- •10.2 TMS
- •10.2.1 rTMS
- •10.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.2 Deep TMS
- •10.2.2.1 Efficacy
- •10.2.2.2 Safety
- •10.2.2.3 Treatment Regimen
- •10.2.2.4 Clinical Recommendations
- •10.2.3 Priming TMS
- •10.2.3.1 Efficacy
- •10.2.3.2 Safety
- •10.2.3.3 Treatment Regimen
- •10.2.3.4 Clinical Recommendations
- •10.2.4 Synchronized TMS
- •10.2.4.1 Efficacy
- •10.2.4.2 Safety
- •10.2.4.3 Treatment Regimen
- •10.2.4.4 Clinical Recommendations
- •10.2.5 TBS
- •10.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.6 Magnetic Seizure Therapy (MST)
- •10.3 tDCS
- •10.3.1 Conventional tDCS
- •10.3.1.1 Efficacy
- •10.3.1.2 Safety
- •10.3.1.3 Treatment Regimen
- •10.3.1.4 Clinical Recommendations
- •10.3.2 HD-tDCS
- •10.3.2.1 Efficacy
- •10.3.2.2 Safety
- •10.3.2.3 Clinical Recommendations
- •10.4 TMS versus tDCS
- •10.4.1 Efficacy
- •10.4.2 Safety
- •10.5 Conclusion
- •References
- •11: Post-traumatic Stress Disorder
- •11.1 Introduction
- •11.2 TMS
- •11.2.1 rTMS
- •11.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.2 Deep TMS
- •11.2.2.1 Efficacy
- •11.2.2.2 Safety
- •11.2.2.3 Treatment Regimen
- •11.2.2.4 Clinical Recommendations
- •11.2.3 Priming TMS
- •11.2.3.1 Efficacy
- •11.2.3.2 Safety
- •11.2.3.3 Treatment Regimen
- •11.2.3.4 Clinical Recommendations
- •11.2.4 Synchronized TMS
- •11.2.4.1 Efficacy
- •11.2.4.2 Safety
- •11.2.4.3 Treatment Regimen
- •11.2.4.4 Clinical Recommendations
- •11.2.5 TBS
- •11.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.5.3 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.6 MST
- •11.2.6.1 Efficacy
- •11.2.6.2 Safety
- •11.2.6.3 Treatment Regimen
- •11.2.6.4 Clinical Recommendations
- •11.3 tDCS
- •11.3.1 Conventional tDCS
- •11.3.1.1 Efficacy
- •11.3.1.2 Safety
- •11.3.1.3 Treatment Regimen
- •11.3.1.4 Clinical Recommendations
- •11.3.2 HD-tDCS
- •11.3.2.1 Efficacy
- •11.3.2.2 Safety
- •11.3.2.3 Treatment Regimen
- •11.3.2.4 Clinical Recommendations
- •11.4 TMS vs. tDCS
- •11.4.1 Efficacy
- •11.4.2 Safety
- •11.5 ECT
- •11.5.1 Efficacy
- •11.5.2 Safety
- •11.5.3 Treatment Regimen
- •11.5.4 Clinical Recommendations
- •11.6 Conclusion
- •References
- •12: Sleep Disorders
- •12.1 Introduction
- •12.2 TMS
- •12.2.1 rTMS
- •12.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •12.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •12.2.1.3 Accelerated rTMS
- •12.2.2 Deep TMS
- •12.2.3 Priming TMS
- •12.2.4 Synchronised TMS
- •12.2.5 TBS
- •12.2.5.1 iTBS
- •12.2.5.2 Accelerated iTBS
- •12.2.5.3 cTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •12.2.5.4 Bilateral TBS
- •12.2.6 MST
- •12.3 tDCS
- •12.3.1 Efficacy
- •12.3.2 Safety
- •12.3.3 Treatment Regimen
- •12.3.4 Clinical Recommendations
- •12.4 TMS Combined tDCS
- •12.4.1 Efficacy
- •12.4.2 Safety
- •12.5 Conclusion
- •References
- •13: Neurocognitive Disorders
- •13.1 Introduction
- •13.2 TMS
- •13.2.1 TMS
- •13.2.1.1 Conventional rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •13.2.1.2 Accelerated rTMS
- •13.2.2 Deep TMS
- •13.2.2.1 Efficacy
- •13.2.2.2 Safety
- •13.2.2.3 Treatment Regimen
- •13.2.2.4 Clinical Recommendations
- •13.2.3 Priming TMS
- •13.2.4 Synchronized TMS
- •13.2.5 iTBS
- •13.2.5.1 Efficacy
- •13.2.5.2 Safety
- •13.2.5.3 Treatment Regimen
- •13.2.5.4 Clinical Recommendations
- •13.2.6 Magnetic Seizure Therapy
- •13.3.1 Conventional tDCS
- •13.3.1.1 Efficacy
- •13.3.1.2 Safety
- •13.3.1.3 Treatment Regimen
- •13.3.1.4 Clinical Recommendations
- •13.3.2 HD-tDCS
- •13.3.2.1 Efficacy
- •13.3.2.2 Safety
- •13.3.2.3 Treatment Regimen
- •13.3.2.4 Clinical Recommendations
- •13.4 TMS vs. tDCS
- •13.4.1 Efficacy
- •13.4.2 Safety
- •13.5 Conclusion
- •References

172
38. Tsai TY, Wang TY, Liu YC, Lee PW, Chang WH, Lu TH, Tseng HH, Lee SY, Chang YH,
Yang Y, Chen PS, Chen KC, Yang YK, Lu RB.Add-on repetitive transcranial magnetic
stimulation in patients with opioid use disorder undergoing methadone maintenance therapy. Am J Drug Alcohol Abuse. 2021;47:330–43.
39. Sayette MA.The role of craving in substance use disorders: theoretical and methodological
issues. Annu Rev Clin Psychol. 2016;12:407–33.
40. Rosenberg O, Klein LD, Dannon PN.Deep transcranial magnetic stimulation for the treatment of pathological gambling. Psychiatry Res. 2013;206:111–3.
41. Pettorruso M, Martinotti G, Montemitro C, De Risio L, Spagnolo PA, Gallimberti L, Fanella
F, Bonci A, Di Giannantonio M.Multiple sessions of high-frequency repetitive transcranial
magnetic stimulation as a potential treatment for gambling addiction: a 3-month, feasibility
study. Eur Addict Res. 2020;26:52–6.
42. Salerno L, Grassi E, Makris N, Pallanti S.A theta burst stimulation on Pre-SMA: proofof-concept of transcranial magnetic stimulation in gambling disorder. J Gambl Stud.
2022;38:1529–37.
43. Concerto C, Signorelli MS, Chiarenza C, Ciancio A, Francesco AD, Mineo L, Rodolico A,
Torrisi G, Caponnetto P, Pennisi M, Lanza G, Petralia A.Transcranial magnetic stimulation
for the treatment of gambling disorder: a systematic review. J Integr Neurosci. 2023;22:164.
44. Cuppone D, Gómez Pérez LJ, Cardullo S, Cellini N, Sarlo M, Soldatesca S, Chindamo S,
Madeo G, Gallimberti L.The role of repetitive transcranial magnetic stimulation (rTMS) in
the treatment of behavioral addictions: Two case reports and review of the literature. J Behav
Addict. 2021;10:361–70.
45. Abdelrahman AA, Noaman M, Fawzy M, Moheb A, Karim AA, Khedr EM.A double-blind
randomized clinical trial of high frequency rTMS over the DLPFC on nicotine dependence,
anxiety and depression. Sci Rep. 2021;11:1640.
46. Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, Zangen A.Smoking
cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and
insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014;76:742–9.
47. Lin J, Liu X, Li H, Yu L, Shen M, Lou Y, Xie S, Chen J, Zhang R, Yuan TF.Chronic repetitive transcranial magnetic stimulation (rTMS) on sleeping quality and mood status in drug
dependent male inpatients during abstinence. Sleep Med. 2019;58:7–12.
48. Gay A, Cabe J, De Chazeron I, Lambert C, Defour M, Bhoowabul V, Charpeaud T, Tremey A,
Llorca PM, Pereira B, Brousse G.Repetitive Transcranial Magnetic Stimulation (rTMS) as a
promising treatment for craving in stimulant drugs and behavioral addiction: a meta-analysis.
J Clin Med. 2022;11
49. Alberto GE, Klorig DC, Goldstein AT, Godwin DW.Alcohol withdrawal produces changes
in excitability, population discharge probability, and seizure threshold. Alcohol Clin Exp Res
(Hoboken). 2023;47:211–8.
50. Shen Y, Cao X, Zeng NN, Wang Y, Zhang H, Zangen A, Yuan TF.Emergence of sexual
dreams and emission following deep transcranial magnetic stimulation over the medial prefrontal and cingulate cortices. CNS Neurol Disord Drug Targets. 2021;20:310–1.
51. Cogné M, Aupy J, Gil-Jardiné C, Glize B.Thirst induced by low frequency right hemisphere
focal rTMS.Brain Stimul. 2018;11:623–4.
52. Steele VR, Maxwell AM, Ross TJ, Moussawi K, Abulseoud OO, Stein EA, Salmeron
BJ.Report of transient events in a cocaine-dependent volunteer who received iTBS.Brain
Stimul. 2018;11:631–3.
53. Soleimani G, Nitsche MA, Bergmann TO, Towhidkhah F, Violante IR, Lorenz R, Kuplicki R,
Tsuchiyagaito A, Mulyana B, Mayeli A, Ghobadi-Azbari P, Mosayebi-Samani M, Zilverstand
A, Paulus MP, Bikson M, Ekhtiari H.Closing the loop between brain and electrical stimulation: towards precision neuromodulation treatments. Transl Psychiatry. 2023;13:279.
54. Zack M, Cho SS, Parlee J, Jacobs M, Li C, Boileau I, Strafella A.Effects of high frequency
repeated transcranial magnetic stimulation and continuous theta burst stimulation on gambling reinforcement, delay discounting, and stroop interference in men with pathological
gambling. Brain Stimul. 2016;9:867–75.
T. Chen et al.

6 Addictive Disorders
55. Sauvaget A, Bulteau S, Guilleux A, Leboucher J, Pichot A, Valrivière P, Vanelle JM, SébilleRivain V, Grall-Bronnec M.Both active and sham low-frequency rTMS single sessions
over the right DLPFC decrease cue-induced cravings among pathological gamblers seeking treatment: a randomized, double-blind, sham-controlled crossover trial. J Behav Addict.
2018;7:126–36.
56. Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, Filipović
SR, Grefkes C, Hasan A, Hummel FC, Jääskeläinen SK, Langguth B, Leocani L, Londero
A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U,
Paulus W, Poulet E, Quartarone A, Rachid F, Rektorová I, Rossi S, Sahlsten H, Schecklmann
M, Szekely D, Ziemann U. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol.
2020;131:474–528.
57. Tikka SK, Siddiqui MA, Garg S, Pattojoshi A, Gautam M.Clinical practice guidelines for the
therapeutic use of repetitive transcranial magnetic stimulation in neuropsychiatric disorders.
Indian J Psychiatry. 2023;65:270–88.
58. Cohen SL, Bikson M, Badran BW, George MS. A visual and narrative timeline of US
FDA milestones for Transcranial Magnetic Stimulation (TMS) devices. Brain Stimul.
2022;15:73–5.
59. Liu W, Mao Y, Wei D, Yang J, Du X, Xie P, Qiu J.Structural asymmetry of dorsolateral prefrontal cortex correlates with depressive symptoms: evidence from healthy individuals and
patients with major depressive disorder. Neurosci Bull. 2016;32:217–26.
60. Wing VC, Bacher I, Wu BS, Daskalakis ZJ, George TP. High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophr Res.
2012;139:264–6.
61. Kozak K, Sharif-Razi M, Morozova M, Gaudette EV, Barr MS, Daskalakis ZJ, Blumberger
DM, George TP. Effects of short-term, high-frequency repetitive transcranial magnetic
stimulation to bilateral dorsolateral prefrontal cortex on smoking behavior and cognition in
patients with schizophrenia and non-psychiatric controls. Schizophr Res. 2018;197:441–3.
62. Bidzinski KK, Lowe DJE, Sanches M, Sorkhou M, Boileau I, Kiang M, Blumberger DM,
Remington G, Ma C, Castle DJ, Rabin RA, George TP. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia.
Schizophrenia (Heidelb). 2022;8:2.
63. Botelho AO, Bernardo Ribeiro F, Soares Machado J, Souza DCB.Functional connectivity
alterations in individuals with gaming disorder assessed by functional magnetic resonance
imaging: a systematic review. J Addict Dis. 2025;43:4–11.
64. Liu Q, Shen Y, Cao X, Li Y, Chen Y, Yang W, Yuan TF.Either at left or right, both high
and low frequency rTMS of dorsolateral prefrontal cortex decreases cue induced craving for
methamphetamine. Am J Addict. 2017;26:776–9.
65. Tolomeo S, Yu R.Brain network dysfunctions in addiction: a meta-analysis of resting-state
functional connectivity. Transl Psychiatry. 2022;12:41.
66. Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, Nejad R, Pankow H,
Choi E, Aaron H, Espil FM, Pannu J, Xiao X, Duvio D, Solvason HB, Hawkins J, Guerra
A, Jo B, Raj KS, Phillips AL, Barmak F, Bishop JH, Coetzee JP, Debattista C, Keller J,
Schatzberg AF, Sudheimer KD, Williams NR.Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry. 2020;177:716–26.
67. Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, Veerapal C, Khan N,
Cherian K, Felber E, Brown R, Choi E, King S, Pankow H, Bishop JH, Azeez A, Coetzee J,
Rapier R, Odenwald N, Carreon D, Hawkins J, Chang M, Keller J, Raj K, Debattista C, Jo B,
Espil FM, Schatzberg AF, Sudheimer KD, Williams NR.Stanford Neuromodulation Therapy
(SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022;179:132–41.
68. Wu GR, Baeken C, Van Schuerbeek P, De Mey J, Bi M, Herremans SC.Accelerated repetitive
transcranial magnetic stimulation does not inuence grey matter volumes in regions related
to alcohol relapse: an open-label exploratory study. Drug Alcohol Depend. 2018;191:210–4.
173

174
69. Herremans SC, Van Schuerbeek P, De Raedt R, Matthys F, Buyl R, De Mey J, Baeken C.The
impact of accelerated right prefrontal high-frequency repetitive transcranial magnetic stimulation (rTMS) on cue-reactivity: An fMRI study on craving in recently detoxied alcoholdependent patients. PLoS One. 2015;10:e0136182.
70. Van Rooij SJH, Arulpragasam AR, Mcdonald WM, Philip NS.Accelerated TMS – moving
quickly into the future of depression treatment. Neuropsychopharmacology. 2024;49:128–37.
71. Zangen A, Roth Y, Voller B, Hallett M. Transcranial magnetic stimulation of deep brain
regions: evidence for efcacy of the H-coil. Clin Neurophysiol. 2005;116:775–9.
72. Deng ZD, Lisanby SH, Peterchev AV.Coil design considerations for deep transcranial magnetic stimulation. Clin Neurophysiol. 2014;125:1202–12.
73. Addolorato G, Antonelli M, Cocciolillo F, Vassallo GA, Tarli C, Sestito L, Mirijello A,
Ferrulli A, Pizzuto DA, Camardese G, Miceli A, Diana M, Giordano A, Gasbarrini A, Di
Giuda D.Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur
Neuropsychopharmacol. 2017;27:450–61.
74. Girardi P, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A,
Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V, Ferri VR, Ferracuti S,
Zangen A, Angeletti G.Add-on deep transcranial magnetic stimulation (dTMS) in patients
with dysthymic disorder comorbid with alcohol use disorder: a comparison with standard
treatment. World J Biol Psychiatry. 2015;16:66–73.
75. Kim WS, Paik NJ.Safety review for clinical application of repetitive transcranial magnetic
stimulation. Brain Neurorehabil. 2021;14:e6.
76. Zhang JJ, Bai Z, Fong KNK.Methodological considerations of priming repetitive transcranial magnetic stimulation protocols in clinical populations. Gen Psychiatr. 2024;37:e101237.
77. Fitzgerald PB, Hoy K, Mcqueen S, Herring S, Segrave R, Been G, Kulkarni J, Daskalakis
ZJ.Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. J Clin Psychopharmacol.
2008;28:52–8.
78. Kourosh-Arami M, Komaki A, Gholami M.Addiction-induced plasticity in underlying neural circuits. Neurol Sci. 2022;43:1605–15.
79. Fingelkurts AA, Fingelkurts AA.Altered structure of dynamic electroencephalogram oscillatory pattern in major depression. Biol Psychiatry. 2015;77:1050–60.
80. Diego MA, Field T, Hernandez-Reif M.CES-D depression scores are correlated with frontal
EEG alpha asymmetry. Depress Anxiety. 2001;13:32–7.
81. Ulrich G, Renfordt E, Zeller G, Frick K.Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question. Pharmacopsychiatry. 1984;17:178–83.
82. Zrenner B, Zrenner C, Gordon PC, Belardinelli P, Mcdermott EJ, Soekadar SR, Fallgatter AJ,
Ziemann U, Müller-Dahlhaus F. Brain oscillation-synchronized stimulation of the left dorsolateral prefrontal cortex in depression using real-time EEG-triggered TMS.Brain Stimul.
2020;13:197–205.
83. Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal
AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV,
O’reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter
AM, Lisanby SH, George MS.Efcacy and safety of low-eld synchronized transcranial magnetic stimulation (sTMS) for treatment of major depression. Brain Stimul. 2015;8:787–94.
84. George MS, Huffman S, Doose J, Sun X, Dancy M, Faller J, Li X, Yuan H, Goldman RI,
Sajda P, Brown TR. EEG synchronized left prefrontal transcranial magnetic stimulation
(TMS) for treatment resistant depression is feasible and produces an entrainment dependent clinical response: a randomized controlled double blind clinical trial. Brain Stimul.
2023;16:1753–63.
T. Chen et al.

6 Addictive Disorders
85. Philip NS, Aiken EE, Kelley ME, Burch W, Waterman L, Holtzheimer PE.Synchronized
transcranial magnetic stimulation for posttraumatic stress disorder and comorbid major
depression. Brain Stimul. 2019;12:1335–7.
86. Jampel J, Quinn MJ, Catalano JL, Benca-Bachman CB, Brick L, Philip NS, Swift RM,
Mcgeary JE. Synchronised transcranial magnetic stimulation for substance use-disordered veterans: protocol for the pilot sham-controlled acceptability trial. BMJ Open.
2023;13:e066175.
87. Li X, Hartwell KJ, Henderson S, Badran BW, Brady KT, George MS.Two weeks of imageguided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation
improves smoking cessation: a double-blind, sham-controlled, randomized clinical trial.
Brain Stimul. 2020;13:1271–9.
88. Chung SW, Hoy KE, Fitzgerald PB.Theta-burst stimulation: a new form of TMS treatment
for depression? Depress Anxiety. 2015;32:182–92.
89. Lee CW, Wu HF, Chu MC, Chung YJ, Mao WC, Li CT, Lin HC.Mechanism of intermittent
theta-burst stimulation in synaptic pathology in the prefrontal cortex in an antidepressantresistant depression rat model. Cereb Cortex. 2021a;31:575–90.
90. Sheridan GK, Moeendarbary E, Pickering M, O’Connor JJ, Murphy KJ.Theta-burst stimulation of hippocampal slices induces network-level calcium oscillations and activates analogous gene transcription to spatial learning. PLoS One. 2014;9:e100546.
91. Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska
Y, Kennedy SH, Lam RW, Daskalakis ZJ, Downar J. Effectiveness of theta burst versus
high-frequency repetitive transcranial magnetic stimulation in patients with depression
(THREE-D): a randomised non-inferiority trial. Lancet. 2018;391:1683–92.
92. Liu Q, Sun H, Hu Y, Wang Q, Zhao Z, Dong D, Shen Y.Intermittent theta burst stimulation
vs. high-frequency repetitive transcranial magnetic stimulation in the treatment of methamphetamine patients. Front Psych. 2022;13:842947.
93. Ren Z, Mu L, Wang L, Xia L, Song P, Wang Y, Li J, Duan F, Li H, Tang H, Wang W, Zhu L,
Zhang L, Song X, Wang Y, Zhao W, Zhu Y, Wang Z, Shao W, Zhang X, Jiao D.Predictive role
of impulsivity, anxiety, and depression in the efcacy of intermittent theta burst transcranial
magnetic stimulation modalities for treating methamphetamine use disorder: A randomized
clinical trial. J Subst Use Addict Treat. 2024;156:209189.
94. Sun Y, Wang H, Ku Y.Intermittent theta-burst stimulation increases the working memory
capacity of methamphetamine addicts. Brain Sci. 2022;12
95. Zhao D, Li Y, Liu T, Voon V, Yuan TF.Twice-daily theta burst stimulation of the dorsolateral prefrontal cortex reduces methamphetamine craving: a pilot study. Front Neurosci.
2020;14:208.
96. Dieler AC, Dresler T, Joachim K, Deckert J, Herrmann MJ, Fallgatter AJ.Can intermittent
theta burst stimulation as add-on to psychotherapy improve nicotine abstinence? Results
from a pilot study. Eur Addict Res. 2014;20:248–53.
97. Dong L, Chen WC, Su H, Wang ML, Du C, Jiang XR, Mei SF, Chen SJ, Liu XJ, Liu
XB.Intermittent theta burst stimulation to the left dorsolateral prefrontal cortex improves
cognitive function in polydrug use disorder patients: a randomized controlled trial. Front
Psych. 2023;14:1156149.
98. Kang T, Ding X, Zhao J, Li X, Xie R, Jiang H, He L, Hu Y, Liang J, Zhou G, Huo X.Inuence
of improved behavioral inhibition on decreased cue-induced craving in heroin use disorder:
A preliminary intermittent theta burst stimulation study. J Psychiatr Res. 2022;152:375–83.
99. Sanna A, Fattore L, Badas P, Corona G, Cocco V, Diana M.Intermittent theta burst stimulation
of the prefrontal cortex in cocaine use disorder: a pilot study. Front Neurosci. 2019;13:765.
100. Upton S, Brown AA, Ithman M, Newman-Norlund R, Sahlem G, Prisciandaro JJ, Mcclure
EA, Froeliger B. Effects of hyperdirect pathway theta burst transcranial magnetic stimulation on inhibitory Control, craving, and smoking in adults with nicotine dependence: a
double-blind, randomized crossover trial. Biol Psychiatry Cogn Neurosci Neuroimaging.
2023b;8:1156–65.
175

176
101. Chen T, Su H, Wang L, Li X, Wu Q, Zhong N, Du J, Meng Y, Duan C, Zhang C, Shi W, Xu
D, Song W, Zhao M, Jiang H. Modulation of methamphetamine-related attention bias by
intermittent theta-burst stimulation on left dorsolateral prefrontal cortex. Front Cell Dev Biol.
2021;9:667476.
102. Mizoguchi H, Yamada K.Methamphetamine use causes cognitive impairment and altered
decision-making. Neurochem Int. 2019;124:106–13.
103. Upton S, Brown AA, Golzy M, Garland EL, Froeliger B.Right inferior frontal gyrus thetaburst stimulation reduces smoking behaviors and strengthens fronto-striatal-limbic restingstate functional connectivity: a randomized crossover trial. Front Psych. 2023a;14:1166912.
104. Mikellides G, Michael P, Psalta L, Stefani A, Schuhmann T, Sack AT.Accelerated intermittent theta burst stimulation in smoking cessation: no differences between active and placebo
stimulation when using advanced placebo coil technology. A double-blind follow-up study.
Int J Clin Health Psychol. 2023;23:100351.
105. Steele VR, Maxwell AM, Ross TJ, Stein EA, Salmeron BJ.Accelerated intermittent thetaburst stimulation as a treatment for cocaine use disorder: a proof-of-concept study. Front
Neurosci. 2019;13:1147.
106. Cole E, O’sullivan SJ, Tik M, Williams NR.Accelerated theta burst stimulation: safety, efcacy, and future advancements. Biol Psychiatry. 2024;95:523–35.
107. Mcneill A, Monk RL, Qureshi AW, Makris S, Heim D.Continuous theta burst transcranial
magnetic stimulation of the right dorsolateral prefrontal cortex impairs inhibitory control and
increases alcohol consumption. Cogn Affect Behav Neurosci. 2018;18:1198–206.
108. Mcneill AM, Monk RL, Qureshi AW, Makris S, Cazzato V, Heim D.Correction to: elevated
ad libitum alcohol consumption following continuous theta burst stimulation to the left-dorsolateral prefrontal cortex is partially mediated by changes in craving. Cogn Affect Behav
Neurosci. 2021;21:1319.
109. Ankit A, Das B, Dey P, Kshitiz KK, Khess CRJ.Efcacy of continuous theta burst stimulation – repetitive transcranial magnetic stimulation on the orbitofrontal cortex as an adjunct to
naltrexone in patients of opioid use disorder and its correlation with serum BDNF levels: a
sham-controlled study. J Addict Dis. 2022;40:373–81.
110. Mccalley DM, Kaur N, Wolf JP, Contreras IE, Book SW, Smith JP, Hanlon CA.Medial
prefrontal cortex theta burst stimulation improves treatment outcomes in alcohol use disorder: a double-blind, sham-controlled neuroimaging study. Biol Psychiatry Glob Open Sci.
2023;3:301–10.
111. Hanlon CA, Dowdle LT, Correia B, Mithoefer O, Kearney-Ramos T, Lench D, Grifn M,
Anton RF, George MS.Left frontal pole theta burst stimulation decreases orbitofrontal and
insula activity in cocaine users and alcohol users. Drug Alcohol Depend. 2017;178:310–7.
112. Blumberger DM, Mulsant BH, Thorpe KE, Mcclintock SM, Konstantinou GN, Lee HH,
Nestor SM, Noda Y, Rajji TK, Trevizol AP, Vila-Rodriguez F, Daskalakis ZJ, Downar
J.Effectiveness of standard sequential bilateral repetitive transcranial magnetic stimulation
vs bilateral theta burst stimulation in older adults with depression: The FOUR-D randomized
noninferiority clinical trial. JAMA Psychiatry. 2022;79:1065–73.
113. Elnazali M, Veerakumar A, Blair M, Pearce EL, Kim N, Sebastian S, Santo JB, Rybak YE,
Burhan AM.Unilateral and bilateral theta burst stimulation for treatment-resistant depression: follow up on a naturalistic observation study. J Psychiatr Res. 2024;180:387–93.
114. Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA.Safety and feasibility of magnetic seizure
therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003;28:1852–65.
115. Backhouse FA, Noda Y, Knyahnytska Y, Farzan F, Downar J, Rajji TK, Mulsant BH,
Daskalakis ZJ, Blumberger DM.Characteristics of ictal EEG in Magnetic Seizure Therapy at
various stimulation frequencies. Clin Neurophysiol. 2018;129:1770–9.
116. Sun Y, Blumberger DM, Mulsant BH, Rajji TK, Fitzgerald PB, Barr MS, Downar J, Wong
W, Farzan F, Daskalakis ZJ.Magnetic seizure therapy reduces suicidal ideation and produces
neuroplasticity in treatment-resistant depression. Transl Psychiatry. 2018;8:253.
T. Chen et al.

6 Addictive Disorders
117. Cai DB, Yang XH, Shi ZM, Nie S, Xu R, Qin XD, Huang X, Huang XB, Zheng W.Comparison
of efcacy and safety of magnetic seizure therapy and electroconvulsive therapy for depression: a systematic review. J Pers Med. 2023;13
118. Carroll BT, Hassell J, Ali A.Treatment options for methamphetamine-associated catatonia.
Ann Clin Psychiatry. 2023;35:e1–2.
119. Grelotti DJ, Kanayama G, Pope HG Jr. Remission of persistent methamphetamine-induced
psychosis after electroconvulsive therapy: presentation of a case and review of the literature.
Am J Psychiatry. 2010;167:17–23.
120. Roshanaei-Moghaddam B, Pauly MC. Treatment of methamphetamine dependence with
electroconvulsive therapy (ECT) in Iran: a critical note. Iran J Psychiatry. 2014;9:184–7.
121. Fregni F, El-Hagrassy MM, Pacheco-Barrios K, Carvalho S, Leite J, Simis M, Brunelin
J, Nakamura-Palacios EM, Marangolo P, Venkatasubramanian G, San-Juan D, Caumo W,
Bikson M, Brunoni AR, Neuromodulation Center Working G.Evidence-based guidelines and
secondary meta-analysis for the use of transcranial direct current stimulation in neurological
and psychiatric disorders. Int J Neuropsychopharmacol. 2021;24:256–313.
122. Klauss J, Penido Pinheiro LC, Silva Merlo BL, Correia Santos GDA, Fregni F, Nitsche MA,
Miyuki Nakamura-Palacios E.A randomized controlled trial of targeted prefrontal cortex
modulation with tDCS in patients with alcohol dependence. Int J Neuropsychopharmacol.
2014;17:1793–803.
123. Klauss J, Anders QS, Felippe LV, Nitsche MA, Nakamura-Palacios EM.Multiple sessions of
transcranial direct current stimulation (tDCS) reduced craving and relapses for alcohol use:
a randomized placebo-controlled trial in alcohol use disorder. Front Pharmacol. 2018;9:716.
124. Dubuson M, Kornreich C, Vanderhasselt M-A, Baeken C, Wyckmans F, Dousset C, Hanak
C, Veeser J, Campanella S, Chatard A.Transcranial direct current stimulation combined with
alcohol cue inhibitory control training reduces the risk of early alcohol relapse: a randomized
placebo-controlled clinical trial. Brain Stimul. 2021;14:1531–43.
125. Uyl TE, Gladwin TE, Wiers RW.Electrophysiological and behavioral effects of combined
transcranial direct current stimulation and alcohol approach bias retraining in hazardous
drinkers. Alcohol Clin Exp Res. 2016;40:2124–33.
126. Witkiewitz K, Stein ER, Votaw VR, Wilson AD, Roos CR, Gallegos SJ, Clark VP, Claus
ED. Mindfulness-based relapse prevention and transcranial direct current stimulation to
reduce heavy drinking: a double-blind sham-controlled randomized trial. Alcohol Clin Exp
Res. 2019;43:1296–307.
127. Uyl TE, Gladwin TE, Rinck M, Lindenmeyer J, Wiers RW.A clinical trial with combined
transcranial direct current stimulation and alcohol approach bias retraining. Addict Biol.
2017;22:1632–40.
128. Uyl TE, Gladwin TE, Lindenmeyer J, Wiers RW.A clinical trial with combined transcranial
direct current stimulation and attentional bias modication in alcohol-dependent patients.
Alcohol Clin Exp Res. 2018;42:1961–9.
129. Kang N, Kim RK, Kim HJ.Effects of transcranial direct current stimulation on symptoms of
nicotine dependence: a systematic review and meta-analysis. Addict Behav. 2019;96:133–9.
130. Boggio PS, Liguori P, Sultani N, Rezende L, Fecteau S, Fregni F.Cumulative priming effects
of cortical stimulation on smoking cue-induced craving. Neurosci Lett. 2009;463:82–6.
131. Mondino M, Luck D, Grot S, Januel D, Suaud-Chagny M-F, Poulet E, Brunelin J.Effects of
repeated transcranial direct current stimulation on smoking, craving and brain reactivity to
smoking cues. Sci Rep. 2018;8:8724.
132. Ghorbani Behnam S, Mousavi SA, Emamian MH.The effects of transcranial direct current
stimulation compared to standard bupropion for the treatment of tobacco dependence: a randomized sham-controlled trial. Eur Psychiatry. 2019;60:41–8.
133. Batista EK, Klauss J, Fregni F, Nitsche MA, Nakamura-Palacios EM.A randomized placebocontrolled trial of targeted prefrontal cortex modulation with bilateral tDCS in patients with
crack-cocaine dependence. Int J Neuropsychopharmacol. 2015;18:pyv066.
177

178
134. Gaudreault PO, Sharma A, Datta A, Nakamura-Palacios EM, King S, Malaker P, Wagner A,
Vasa D, Parvaz MA, Parra LC, Alia-Klein N, Goldstein RZ.A double-blind sham-controlled
phase 1 clinical trial of tDCS of the dorsolateral prefrontal cortex in cocaine inpatients: craving, sleepiness, and contemplation to change. Eur J Neurosci. 2021;53:3212–30.
135. Verveer I, Veen FM, Shahbabaie A, Remmerswaal D, Franken IHA.Multi-session electrical
neuromodulation effects on craving, relapse and cognitive functions in cocaine use disorder:
a randomized, sham-controlled tDCS study. Drug Alcohol Depend. 2020;217:108429.
136. Alizadehgoradel J, Nejati V, Movahed FS, Imani S, Taherifard M, Mosayebi-Samani M,
Vicario CM, Nitsche MA, Salehinejad MA.Repeated stimulation of the dorsolateral-prefrontal cortex improves executive dysfunctions and craving in drug addiction: a randomized,
double-blind, parallel-group study. Brain Stimul. 2020;13:582–93.
137. Anaraki MR, Dolatshahi B, Nosratabadi M, Yalghouzaghaji MN, Mashhadi SR.Repeated
transcranial direct current stimulation (tDCS) on methamphetamine craving: a randomized,
sham-controlled study. Iran Rehabil J. 2019;
138. Xu X, Ding X, Chen L, Chen T, Su H, Li X, Ye Y, Shi W, Ji J, Zhao M.The transcranial direct
current stimulation over prefrontal cortex combined with the cognitive training reduced the
cue-induced craving in female individuals with methamphetamine use disorder: a randomized controlled trial. J Psychiatr Res. 2021;134:102–10.
139. Eskandari Z, Mostafavi H, Hosseini M, Mousavi SE, Ramazani S, Dadashi M.A shamcontrolled clinical trial to examine the effect of bilateral tD.J Addict Dis. 2021;39:347–56.
140. Taremian F, Nazari S, Moradveisi L, Moloodi R.Transcranial direct current stimulation on
opium craving, depression, and anxiety: a preliminary study. J ECT. 2019;35:201–6.
141. Jeong J-E, Park C-H, Kim M, Cho H, Pyeon A, Jung S, Jung D, Kim J-Y, Choi J, Chun J-W,
Ahn K-J, Kim D-J.Effects of bilateral tDCS over DLPFC on response inhibition, craving,
and brain functional connectivity in Internet gaming disorder: a randomized, double-blind,
sham-controlled trial with fMRI. 2024
142. Lee J-Y, Jang JH, Choi AR, Chung SJ, Kim B, Park M, Oh S, Jung MH, Choi
J-S.Neuromodulatory effect of transcranial direct current stimulation on resting-state EEG
activity in internet gaming disorder: a randomized, double-blind, sham-controlled parallel
group trial. cerebral cortex. Communications. 2021b;2:tgaa095.
143. Martinotti G, Lupi M, Montemitro C, Miuli A, Di Natale C, Spano MC, Mancini V, Lorusso
M, Stigliano G, Tambelli A, Di Carlo F, Di Caprio L, Fraticelli S, Chillemi E, Pettorruso
M, Sepede G, Giannantonio M.Transcranial direct current stimulation reduces craving in.
J ECT. 2019;
144. Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP,
Kronberg G, Truong D, Boggio P.Safety of transcranial direct current stimulation: evidence
based update 2016. Brain Stimul. 2016;9:641–61.
145. Nitsche MA, Liebetanz D, Lang N, Antal A, Tergau F, Paulus W.Safety criteria for transcranial direct current stimulation (tDCS) in humans. Clin Neurophysiol. 2003;114:2220–2.
author reply 2222-2223
146. Poreisz C, Boros K, Antal A, Paulus W.Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull. 2007;72:208–14.
147. Smith RC, Boules S, Mattiuz S, Youssef M, Tobe RH, Sershen H, Lajtha A, Nolan K,
Amiaz R, Davis JM.Effects of transcranial direct current stimulation (tDCS) on cognition,
symptoms, and smoking in schizophrenia: a randomized controlled stud y. Schizophr Res.
2015;168:260–6.
148. Song S, Zilverstand A, Gui W, Li H-J, Zhou X.Effects of single-session versus multi-session
non-invasive brain stimulation on craving and consumption in individuals with drug addiction, eating disorders or obesity: a meta-analysis. Brain Stimul. 2019;12:606–18.
149. Sreeraj VS, Dinakaran D, Parlikar R, Chhabra H, Selvaraj S, Shivakumar V, Bose A,
Narayanaswamy JC, Venkatasubramanian G.High-denition transcranial direct current simulation (HD-tDCS) for persistent auditory hallucinations in schizophrenia. Asian J Psychiatr.
2018;37:46–50.
T. Chen et al.

6 Addictive Disorders
150. Wong HL, Chan WC, Wong YL, Wong SN, Yung HY, Wong SC, Cheng PC.High-denition
transcranial direct current stimulation-An open-label pilot intervention in alleviating
depressive symptoms and cognitive decits in late-life depression. CNS Neurosci Ther.
2019;25:1244–53.
151. Motes MA, Spence JS, Yeatman K, Jones PM, Lutrell M, O’Hair R, Shakal S, Delarosa BL,
To W, Vanneste S, Kraut MA, Hart J Jr. High-denition transcranial direct current stimulation to improve verbal retrieval decits in chronic traumatic brain injury. J Neurotrauma.
2020;37:170–7.
152. Richardson J, Datta A, Dmochowski J, Parra LC, Fridriksson J.Feasibility of using highdenition transcranial direct current stimulation (HD-tDCS) to enhance treatment outcomes
in persons with aphasia. NeuroRehabilitation. 2015;36:115–26.
153. Frohlich F, Riddle J.Conducting double-blind placebo-controlled clinical trials of transcranial alternating current stimulation (tACS). Transl Psychiatry. 2021;11:1–12.
154. Rossi S, Hallett M, Rossini PM, Pascual-Leone A.Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and
research. Clin Neurophysiol. 2009;120:2008–39.
155. Bergmann TO, Varatheeswaran R, Hanlon CA, Madsen KH, Thielscher A, Siebner
HR.Concurrent TMS-fMRI for causal network perturbation and proof of targe t engagement.
NeuroImage. 2021;237:118093.
156. Strafella R, Momi D, Zomorrodi R, Lissemore J, Noda Y, Chen R, Rajji TK, Grifths JD,
Vila-Rodriguez F, Downar J, Daskalakis ZJ, Blumberger DM, Voineskos D.Identifying neurophysiological markers of intermittent theta-burst stimulation in treatment-resistant depression using transcranial magnetic stimulation- electroencephalography. Biol Psychiatry.
2023:S0006322323012076.
157. Bradley C, Nydam AS, Dux PE, Mattingley JB.State-dependent effects of neural stimulation
on brain function and cognition. Nat Rev Neurosci. 2022;23:459–75.
158. Siddiqi SH, Taylor SF, Cooke D, Pascual-Leone A, George MS, Fox MD.Distinct symptom-specic treatment targets for circuit-based neuromodulation. Am J Psychiatry.
2020;177:435–46.
179

Obsessive-Compulsive Disorder
YiliangZhang, ShumingZhong, ShunkaiLai, DongHuang,
andYanbinJia
Abstract
Obsessive-compulsive disorder (OCD) is a prevalent and debilitating psychiatric
condition that profoundly impacts individuals’ lives. Its complex and multifactorial etiology presents signicant challenges for effective treatment. While many
patients benet from standard interventions such as pharmacological therapies
and psychotherapy, a substantial number remain resistant to treatment, resulting
in poor long-term outcomes. Emerging neurostimulation therapies, encompassing both noninvasive and invasive techniques, offer promising alternatives for
managing OCD.Numerous clinical trials have explored novel neurostimulation
protocols, aiming to improve treatment efcacy. However, ndings remain
inconsistent, and no universally accepted approach has been established. This
underscores the critical need for further research to rene stimulation parameters
and identify factors that inuence individual responsiveness to these interventions. This chapter provides a comprehensive overview of neuromodulation
strategies for OCD, highlighting current advancements, ongoing challenges, and
future directions in this rapidly evolving eld.
7
Keywords
OCD · rTMS · dTMS · TBS · tDCS
Y. Zhang · S. Zhong · S. Lai · D. Huang · Y. Jia (*)
Department of Psychiatry, First Afliated Hospital of Jinan University, Guangzhou, China
© The Author(s), under exclusive license to Springer Nature Singapore Pte
Ltd. 2025
W. Zheng, Y. Ning (eds.), TMS and tDCS for Psychiatric Disorders,
https://doi.org/10.1007/978-981-96-8504-2_7
181

182
Y. Zhang et al.
Abbreviations
ACC anterior cingulate cortex
ahTBS accelerated high-dose Theta Burst Stimulation
aiTBS asymmetric intermittent Theta Burst Stimulation
AMT active motor threshold
BAI Beck Anxiety Inventory
BD Bipolar Disorder
BDI-II Beck Depression Inventory II
CBT cognitive-behavioral therapy
CSTC cortico-striatal-thalamic-cortical
cTBS Continuous TBS
DBS deep brain stimulation
DLPFC dorsolateral prefrontal cortex
dmPFC dorsomedial prefrontal
dTMS Deep Transcranial Magnetic Stimulation
ECT electroconvulsive therapy
EEG electroencephalography
ERP exposure and response prevention
fMRI Functional Magnetic Resonance Imaging
HD-tDCS High-denition transcranial direct current stimulation
HF high-frequency
iTBS intermittent Theta Burst Stimulation
L-DLPFC left dorsolateral prefrontal cortex
LF-R-DLPFC left frontolateral region of the dorsolateral prefrontal cortex
MDD Major Depressive Disorder
MEP motor-evoked potential
MFG middle frontal gyrus
MST Magnetic Seizure Therapy
MT motor threshold
OCD Obsessive–compulsive disorder
OFC orbitofrontal cortex
RCTs Randomized Controlled Trials
RMT resting motor threshold
ROFC right orbitofrontal cortex
rTMS repetitive Transcranial Magnetic Stimulation
SFG superior frontal gyrus
SMA supplementary motor area
SSRIs serotonergic reuptake inhibitors
TBS Theta Burst Stimulation
tDCS transcranial direct current stimulation
TMS transcranial magnetic stimulation
VNS Vagus Nerve Stimulation
YBOCS Yale-Brown Obsessive Compulsive Scale
Соседние файлы в папке Библиотека им академика М.И. Перельмана
